Sarah Katharina Assiba Weiß, Carsten Lange, Nicole Hübscher, Abdullah Al Hasan, Steffen Hallmann, Tobias Klatte
{"title":"[Adjuvant immunotherapy with pembrolizumab for renal cell carcinoma-is the new standard of care cost-effective?? : A health economic analysis].","authors":"Sarah Katharina Assiba Weiß, Carsten Lange, Nicole Hübscher, Abdullah Al Hasan, Steffen Hallmann, Tobias Klatte","doi":"10.1007/s00120-025-02632-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adjuvant pembrolizumab decreases the risk of recurrence and prolongs survival after surgery for high-risk clear cell renal cell carcinoma. Cost-effectiveness analyses evaluate therapy associated risks, toxicity, quality of life, costs of therapies and follow-up regimens and represent an essential adjunct for the evaluation of new therapies. At present, there is no cost effectiveness analysis for adjuvant pembrolizumab within the German healthcare system.</p><p><strong>Methods: </strong>A Markov model was used to evaluate cost-effectiveness. The impact of variables on the cost-effectiveness of therapy were investigated with one-way deterministic and probabilistic sensitivity analysis and thresholds were determined.</p><p><strong>Results: </strong>The adjuvant treatment with pembrolizumab was cost-effective over a 5-year period, with an ICER (incremental cost-effectiveness ratio) of 68,278 €/QALY (quality-adjusted life year) assuming a WTP (willingness to pay) threshold of 100,000 €/QALY.</p><p><strong>Conclusion: </strong>Adjuvant treatment in high-risk patients with pembrolizumab has been shown to be cost-effective when applied within the German health system. It should therefore be offered to all patients with an increased risk for recurrence after curative surgery.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02632-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Adjuvant pembrolizumab decreases the risk of recurrence and prolongs survival after surgery for high-risk clear cell renal cell carcinoma. Cost-effectiveness analyses evaluate therapy associated risks, toxicity, quality of life, costs of therapies and follow-up regimens and represent an essential adjunct for the evaluation of new therapies. At present, there is no cost effectiveness analysis for adjuvant pembrolizumab within the German healthcare system.
Methods: A Markov model was used to evaluate cost-effectiveness. The impact of variables on the cost-effectiveness of therapy were investigated with one-way deterministic and probabilistic sensitivity analysis and thresholds were determined.
Results: The adjuvant treatment with pembrolizumab was cost-effective over a 5-year period, with an ICER (incremental cost-effectiveness ratio) of 68,278 €/QALY (quality-adjusted life year) assuming a WTP (willingness to pay) threshold of 100,000 €/QALY.
Conclusion: Adjuvant treatment in high-risk patients with pembrolizumab has been shown to be cost-effective when applied within the German health system. It should therefore be offered to all patients with an increased risk for recurrence after curative surgery.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
